Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
2.090
-0.070 (-3.24%)
At close: Nov 20, 2024, 4:00 PM
2.000
-0.090 (-4.31%)
Pre-market: Nov 21, 2024, 6:48 AM EST
Incannex Healthcare Employees
Incannex Healthcare had 9 employees as of June 30, 2024. The number of employees increased by 6 or 200.00% compared to the previous year.
Employees
9
Change
6
Growth
200.00%
Revenue / Employee
$9,556
Profits / Employee
-$2,572,556
Market Cap
36.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 9 | 6 | 200.00% |
| Jun 30, 2021 | 3 | 1 | 50.00% |
| Jun 30, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| RAPT Therapeutics | 131 |
| Barinthus Biotherapeutics | 130 |
| NextCure | 82 |
| Lumos Pharma | 33 |
| Iterum Therapeutics | 14 |
| CERo Therapeutics Holdings | 9 |
| OS Therapies | 4 |
| OKYO Pharma | 3 |
IXHL News
- 6 days ago - Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Newsfile Corp
- 7 weeks ago - Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives - Newsfile Corp
- 3 months ago - FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - GlobeNewsWire
- 4 months ago - Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewsWire
- 6 months ago - Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea - GlobeNewsWire